中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

5 records (took 0.012 seconds)

    Therapeutic uses of a C-RAF inhibitor
    1.
    发明授权
    Therapeutic uses of a C-RAF inhibitor 有权

    公开(公告)号：US10973829B2

    公开(公告)日：2021-04-13

    申请号：US16332120

    申请日：2017-09-18

    Applicant: Novartis AG

    Inventor： Giordano Caponigro ,  Vesselina Cooke ,  Matthew John Meyer ,  Darrin Stuart

    IPC: A61K31/5377 ,  A61P35/00 ,  A61K31/4965

    Abstract: The present invention relates to a combination treatment which comprises (a) at least one ERK inhibitor preferably Compound B as described herein, and (b) a c-RAF inhibitor or a pharmaceutically acceptable salt thereof, preferably Compound A, which may be combined into a single pharmaceutical composition or prepared for separate or sequential administration. It includes a c-RAF inhibitor and an ERK inhibitor prepared for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly an advanced solid tumor that harbors a Mitogen-activated protein kinase (MAPK) alteration, and includes methods of using these compounds in combination as well as a commercial package comprising such combination.

    Therapeutic combinations comprising a c-RAF inhibitor
    3.
    发明授权
    Therapeutic combinations comprising a c-RAF inhibitor 有权

    公开(公告)号：US12011449B2

    公开(公告)日：2024-06-18

    申请号：US17191205

    申请日：2021-03-03

    Applicant: Novartis AG

    Inventor： Giordano Caponigro ,  Vesselina Cooke ,  Matthew John Meyer ,  Darrin Stuart

    IPC: A61K31/5377 ,  A61K31/4965 ,  A61P35/00

    CPC classification number: A61K31/5377 ,  A61K31/4965 ,  A61P35/00

    Abstract: The present invention relates to a combination treatment which comprises (a) at least one ERK inhibitor preferably Compound B as described herein, and (b) a c-RAF inhibitor or a pharmaceutically acceptable salt thereof, preferably Compound A, which may be combined into a single pharmaceutical composition or prepared for separate or sequential administration. It includes a c-RAF inhibitor and an ERK inhibitor prepared for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly an advanced solid tumor that harbors a Mitogen-activated protein kinase (MAPK) alteration, and includes methods of using these compounds in combination as well as a commercial package comprising such combination.

Patent Agency Ranking